Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

An Open-label, Multi-center, Expanded Treatment Protocol (ETP) of Ruxolitinib in Patients With Polycythemia Vera Who Are Hydroxyurea Resistant or Intolerant and for Whom no Treatment Alternatives Are Available

Next Previous
Trial Profile

An Open-label, Multi-center, Expanded Treatment Protocol (ETP) of Ruxolitinib in Patients With Polycythemia Vera Who Are Hydroxyurea Resistant or Intolerant and for Whom no Treatment Alternatives Are Available

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 06 Oct 2020

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Ruxolitinib (Primary)
  • Indications Polycythaemia vera
  • Focus Adverse reactions; Expanded access
  • Sponsors Novartis; Novartis Pharmaceuticals

Most Recent Events

  • 04 Dec 2018 Results (Dec 29, 2017) consolidated findings from the Expanded Treatment Protocol study at week 96 data cut off, presented at the 60th Annual Meeting and Exposition of the American Society of Hematology.
  • 04 Dec 2018 Algeria, Argentina, Brazil, Colombia, Croatia, Estonia, Hungary, India, Indonesia, Israel, Italy, Jordan, Lebanon, Morocco, Netherlands, Poland, Romania, Saudi Arabia, Slovakia, Slovenia, South Africa, South Korea, Spain, Taiwan, Tunisia, Venezuela were the planned locations as per European Clinical Trials Database record.
  • 21 Mar 2018 Status changed from recruiting to completed.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top